Cord Blood Registry (CBR), a California Cryobank Life Sciences company, has announced it will acquire Natera’s Evercord™ cord blood business for an undisclosed sum. CBR is the largest newborn stem cell collection and storage company within the United States with more than 875,000 stem cell samples in storage. Natera is a publicly listed company (NASDAQ: NTRA) that specializes in genetic testing services. [Read more…]
Press Releases: Press releases are provided by the issuer and may be published by BioInformant as paid content. The issuer is solely responsible for the content and claims contained within these announcements. BioInformant does not independently verify or endorse the claims made by the issuer. For questions about an individual Press Release or to submit one, write us at [email protected].
Generex Biotechnology Announces First-in-Human Clinical Trial of the ALTuCELL Cellular Therapy Product Altsulin® (Microencapsulated Sertoli Cells)
-
Principal investigator Dr. Jaime Guevara Aguirre, world-renowned expert on growth hormone to conduct the trial of Altsulin® (Microencapsulated Sertoli Cells) in Laron Syndrome Patients
-
Laron Syndrome (aka Laron-type dwarfism) is a rare pediatric orphan disease eligible for the FDA “Golden Ticket”
-
Phase IIa proof-of-concept trial paves the way to commercial development of Sertoli Cells for the treatment of Type I Diabetes
Synthego Launches High-Throughput Induced Pluripotent Stem Cell Genome Engineering
National Institutes of Health awards contract for CRISPR-based disease modeling in iPS cell lines associated with Alzheimer’s, Stem cell pioneer Bill Skarnes joins advisory board
REDWOOD CITY, Calif., Oct. 22, 2019 — Synthego, the leading genome engineering company, announced the launch of genome engineering for induced pluripotent stem (iPS) cells. The new offering expands Synthego’s automated cell editing to achieve unprecedented editing efficiency of iPS cells at an industrial scale. [Read more…]
FUJIFILM Irvine Scientific Announces Construction of a New Cell Culture Media Manufacturing Site in Europe
New facility brings rapid, reliable delivery of cell culture media to European customers
SANTA ANA, California – July 2, 2019: FUJIFILM Irvine Scientific, Inc., a global leader in the innovation, development, and manufacture of cell culture media, announced plans to open a third manufacturing facility located in Tilburg, Netherlands. The company currently has sites in the United States and Japan. Fujifilm’s investment in this project demonstrates its commitment to accelerate development in bioproduction, and cell and gene therapy markets. [Read more…]
CARsgen’s CAR-T Therapy CT053 for R/R Multiple Myeloma is 37th Publicly Announced RMAT
SHANGHAI, Oct. 28, 2019 — CARsgen Therapeutics Co. Ltd., a clinical-stage biopharmaceutical company today announced that the United States Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational CT053 CAR-T cell therapy. CT053 is a fully human anti-BCMA (B Cell Maturation Antigen) autologous chimeric antigen receptor (CAR) T Cell therapy for the treatment of relapsed and/or refractory multiple myeloma (rrMM). [Read more…]
- « Previous Page
- 1
- …
- 109
- 110
- 111
- 112
- 113
- …
- 146
- Next Page »